Replies to post #173734 on Biotech Values

[dav1234]

Myriad Genetics' Prolaris effective in detecting recurring prostate cancer
Myriad Genetics (MYGN) jumped nearly 11.5% today on news its Prolaris genetic testing method proved effective in predicting which men would see a cancer recurrence following radical prostate surgery (also).
A study published in the Journal of Urology said a test which evaluated more than 5,000 patients across 11 clinical studies showed Prolaris proved more effective in predicting the likelihood that cancer would return than a Gleason Score or PSA test.
The study "represents a great advance in the treatment of prostate cancer," according to the study investigator.

http://seekingalpha.com/pr/8985631-myriad-genetics-publishes-prolaris-r-data-in-the-journal-of-urology